Centessa Pharmaceuticals
CNTA
Performance
About Centessa Pharmaceuticals
Centessa Pharmaceuticals is a biotechnology company focused on developing transformative neuroscience medicines, with an asset-centric approach and pipelines targeting sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders. The company emphasizes patient-centric mission and has programs such as Orexin Receptor 2 agonists, including the ORX750 program, supported by its LockBody technology platform. Headquartered with operations in the United States, Centessa pursues innovative research and drug development through a collaboration-driven model and ongoing clinical development. The website highlights its leadership in neuroscience, patient resources, and investor information.
Recent News
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
Sun Pharma to Acquire Organon for $11.75 Bn, Marking India's Largest Overseas Pharma Deal
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
Eli Lilly to Acquire Centessa in $7.8 B Deal, Stock Jumps 45%
Top Biotech Deals in March 2026
Eli Lilly to Spend $6.3 B on Centessa Buy, with up to $1.5 B in Milestone Payouts
Lilly Wants to Bridge Cancer Care Gap with $300M ADC Biotech Buy
STAT+: Pharmalittle: We’re Reading About Pharma Delaying Launches in Europe, Lilly and Biogen Deals, and More
Stocks Soar on Hopes of Iran War Resolution — Plus, Lilly Takes a Big Swing in Sleep Disorders
InsideArbitrage Event Driven Monitor – May 8, 2026
Lilly Adds Gene Delivery Technology to CAR T in up to $7B Kelonia Deal
Eli Lilly to Acquire Centessa, Adding Orexin‑Based Sleep‑Wake Drugs
InsideArbitrage Event Driven Monitor – April 1, 2026
Top Biotech Deals in April 2026
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
FDA Grants Fast Track Approval to Eli Lilly's $149‑$349 Daily Weight‑Loss Pill Foundayo
UK Biotech Could Be Bound for Recovery, BIA Report Reveals